Small molecule · Degrader of p53 (mutant) (TP53) · developed by Aprea Therapeutics
APR-548 is an orally administered prodrug that is converted to the active compound 2-methylene-quinuclidin-3-one, which binds mutant p53 at its DNA-binding domain and restores wild-type p53 structure and activity. It is being studied in myelodysplastic syndromes, alone and in combination with azacitidine.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04638309 | Phase 1 | MDS | Terminated | APRE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
MDSMyelodysplastic Syndromes
Updated Oct 11, 2026. Something wrong or missing? Report it on the APRE page.
See APRE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
APRE catalysts and pipeline →